Is Taltz Approved for Psoriatic Arthritis?
Yes, Taltz (ixekizumab) is FDA-approved for active psoriatic arthritis (PsA) in adults.[1] It targets interleukin-17A (IL-17A) to reduce inflammation in joints and skin.
How Does Taltz Work in Psoriatic Arthritis?
Taltz blocks IL-17A, a cytokine driving PsA inflammation. Clinical trials showed it improves joint pain, swelling, skin clearance, and physical function. In SPIRIT-P1 (biologic-naive patients), 62% achieved ACR20 response at week 24 versus 30% on placebo.[1][2]
Who Can Use Taltz for PsA?
Approved for adults with active PsA, including those who failed TNF inhibitors. Not for children under 18 with PsA. Use alongside methotrexate if tolerated, though monotherapy works.[1]
Common Side Effects in PsA Patients
Upper respiratory infections (15-20%), injection-site reactions (15-20%), nausea (3-5%). Serious risks include infections (e.g., tuberculosis screening required), inflammatory bowel disease flares, and rare hypersensitivity.[1][3] Monitor for fungal infections.
How Does Taltz Compare to Other PsA Treatments?
| Treatment | Target | ACR20 Response (Week 24) | Key Difference |
|-----------|--------|---------------------------|---------------|
| Taltz | IL-17A | 62% (biologic-naive)[2] | Strong skin + joint efficacy |
| Cosentyx | IL-17A | 50-60%[4] | Similar; Taltz faster skin clearance |
| Humira | TNF | 50-62%[4] | Better for some gut involvement |
| Stelara | IL-12/23 | 50%[4] | Dual cytokine; less injection pain |
Taltz excels in skin psoriasis overlap but may worsen IBD history.[1][4]
Dosing and Administration for PsA
160 mg initial dose (two 80 mg injections), then 80 mg every 4 weeks. Self-administered subcutaneously.[1]
Cost and Access for PsA Treatment
List price ~$6,000/month; patient assistance via Lilly Cares lowers to $5 copay for eligible insured. Biosimilars not yet available; patent expires ~2033-2036.[5]DrugPatentWatch.com
When to Talk to Your Doctor About Taltz
Start if moderate-severe PsA persists despite DMARDs. Avoid with active infections or IBD. Long-term data (up to 3 years) shows sustained response in 70%.[2]
Sources:
[1] Taltz Prescribing Information (FDA, 2023). Link
[2] Mease et al., Lancet (2017). Link
[3] Nash et al., Rheumatology (2020). Link
[4] Smolen et al., Ann Rheum Dis (2018). Link
[5] DrugPatentWatch.com. Link